H. Kristensen

Local application of recombinant active-site inhibited human clotting factor VIIa reduces thrombus weight and improves patency in a rabbit venous thrombosis model.

A. Kristensen, U. Hedner, J. Holst, 1998, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

The Significance of TFPI in Clotting Assays – Gomparison and Combination with other Anticoagulants

P. Ostergaard, O. Nordfang, P. Østergaard, 1993, Thrombosis and Haemostasis.

Simultaneous presence of tissue factor pathway inhibitor (TFPI) and low molecular weight heparin has a synergistic effect in different coagulation assays

P. Ostergaard, O. Nordfang, H. Kristensen, 1991, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Is Tissue Factor Pathway Inhibitor Involved in the Antithrombotic Effect of Heparins

O. Nordfang, L. C. Petersen, P. Østergaard, 1993 .

Development and validation of a size exclusion chromatography method for determination of molecular masses and molecular mass distribution in low molecular weight heparin.

E. Tromborg, P. Ostergaard, K. Johansen, 1991, Thrombosis research.

Synergism between full length TFPI and heparin: evidence for TFPI as an important factor for the antithrombotic activity of heparin.

P. Ostergaard, O. Nordfang, P. Østergaard, 1992, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Effect of Tissue Factor Pathway Inhibitor (TFPI) in the HEPTEST® Assay and in an Amidolytic Anti Factor Xa Assay for LMW Heparin

A. Lindahl, U. Abildgaard, O. Nordfang, 1992, Thrombosis and Haemostasis.

Evaluation of Potential Antigenicity of Active-Site-Inhibited Recombinant Human FVIIa (FFR-rFVIIa) in an Immune-Tolerant Rat Model

A. Kristensen, U. Hedner, H. Kristensen, 2002, Thrombosis and Haemostasis.